Inhibition by memantine of the development of persistent oral dyskinesias induced by long‐term haloperidol treatment of rats
Open Access
- 1 October 1996
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 119 (4) , 751-757
- https://doi.org/10.1111/j.1476-5381.1996.tb15736.x
Abstract
1 Tardive dyskinesia (TD) is a serious side-effect of long-term treatment with neuroleptics. To investigate if neuroleptic-induced excessive stimulation of striatal glutamate receptors may underlie TD development, the effect of the NMDA antagonist, memantine (1-amino-3,5-dimethyladamantane), was studied in a rat model of TD. 2 In an acute experiment, six groups of rats were treated daily for 1 week with either vehicle or memantine 20 or 40 mg kg−1 day−1, and on the seventh day they received one injection of either haloperidol 1.0 mg kg−1 i.p. or saline i.p. In a subsequent long-term experiment lasting 20 weeks, the same treatment was continued, except that haloperidol was injected i.m. as decanoate (38 mg kg−1 every 4 weeks) and control rats received sesame oil. The behaviour was videotaped and scored at intervals during both experiments, and for 16 weeks after cessation of the long-term treatment. 3 In the acute experiment, haloperidol decreased motor activity and memantine increased moving and tended to attenuate the immobility induced by haloperidol. Memantine also enhanced the haloperidolinduced increase in the putative TD-analogue vacuous chewing movements (VCM). 4 In the long-term experiment, the most marked effect of haloperidol was a gradual increase in VCM and the increase persisted significantly for 12 weeks after cessation of treatment. Memantine dose-dependently increased VCM and moving during long-term treatment. However, only one week after stopping treatment, both these effects of memantine disappeared. In contrast to rats previously treated with haloperidol alone, rats co-treated with memantine (both doses) and haloperidol had VCM at the level of controls two weeks after stopping treatment. The blood levels of drugs were within the therapeutic range achieved in human subjects. 5 These results suggest that long-lasting changes induced by haloperidol are prevented by memantine, which supports the theory that excessive NMDA receptor stimulation may be a mechanism underlying the development of persistent VCM in rats and maybe also TD in human subjects.Keywords
This publication has 49 references indexed in Scilit:
- The rat model of tardive dyskinesia: Relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatmentLife Sciences, 1995
- Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic‐induced dyskinesiasSynapse, 1994
- Haloperidol-induced morphological changes in striatum are associated with glutamate synapsesBrain Research, 1994
- Glutamate antagonists have different effects on spontaneous locomotor activity in ratsPharmacology Biochemistry and Behavior, 1994
- A ketamine-induced rat model of tardive dyskinesiaProgress in Neurobiology, 1992
- Excitotoxic Mechanisms May Be Involved in the Pathophysiology of Tardive DyskinesiaClinical Neuropharmacology, 1991
- Effects of dopamine D1 and D2 receptor antagonists on oral activity in ratsPharmacology Biochemistry and Behavior, 1989
- Wirkungen oraler Memantin-Gaben auf die Parkinson-Symptomatik: Ergebnisse einer placebo-kontrollierten Multicenter-StudieDeutsche Medizinische Wochenschrift (1946), 1984
- Induction of oral dyskinesias in naive rats by D1 stimulationLife Sciences, 1983
- The action of chlorpromazine and imipramine on rat brain mitochondriaGeneral Pharmacology: The Vascular System, 1979